SHR 1314Alternative Names: SHR-1314
Latest Information Update: 28 Oct 2016
At a glance
- Originator Atridia; Jiangsu Hengrui Medicine Co.
- Class Antipsoriatics; Monoclonal antibodies
- Mechanism of Action Interleukin-17 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Psoriasis
- Preclinical Autoimmune disorders
Most Recent Events
- 01 Aug 2016 Phase-I clinical trials in Psoriasis (In volunteers) in Australia (SC) (NCT02934412)
- 01 Jul 2016 Jiangsu Hengrui Medicine plans a phase I trial for Autoimmune diseases in China